Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gynecologic Oncology

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2016.07.111PMID 27461360
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression

  2015cited by this paper
• Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

  2015cited by this paper
• Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

  2015cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015cited by this paper
• Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.

  2014cited by this paper
• Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth

  2014cited by this paper
• Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

  2014cited by this paper
• Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

  2014cited by this paper
• Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

  2014cited by this paper
• Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma

  2014cited by this paper
• Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

  2014cited by this paper
• Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System

  2014cited by this paper
• Synthetic lethality between CCNE1 amplification and loss of BRCA1

  2013cited by this paper
• Integrated genomic characterization of endometrial carcinoma

  2013cited by this paper
• Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

  2013cited by this paper
• Rsf‐1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development

  2013cited by this paper
• An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

  2012cited by this paper
• CBX7 is a tumor suppressor in mice and humans

  2012cited by this paper
• A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

  2012cited by this paper
• Tumor suppressor activity of CBX7 in lung carcinogenesis

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• CBX7 is a tumor suppressor in mice and humans.

  2012cited by this paper
• Mutual exclusivity analysis identifies oncogenic network modules.

  2012cited by this paper
• An integrated view of cyclin E function and regulation

  2012cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

  2011cited by this paper
• miR-15 and miR-16 Are Direct Transcriptional Targets of E2F1 that Limit E2F-Induced Proliferation by Targeting Cyclin E

  2011cited by this paper
• Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

  2011cited by this paper
• Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines

  2010cited by this paper
• Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer

  2010cited by this paper
• Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase

  2010cited by this paper
• Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer

  2010cited by this paper
• Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

  2010cited by this paper
• The genesis and evolution of high-grade serous ovarian cancer

  2010cited by this paper
• Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer

  2010cited by this paper
• Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

  2010cited by this paper
• TGFβ prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest

  2009cited by this paper
• A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

  2009cited by this paper
• Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

  2009cited by this paper
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

  2009cited by this paper
• Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.

  2009cited by this paper
• TGFbeta prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest.

  2009cited by this paper
• miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes

  2008cited by this paper
• A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

  2008cited by this paper
• A microRNA component of the p53 tumour suppressor network

  2007cited by this paper
• Cyclin E–Associated Kinase Activity Predicts Response to Platinum-Based Chemotherapy

  2007cited by this paper
• Cdc2–cyclin E complexes regulate the G1/S phase transition

  2005cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.

  2005cited by this paper
• E2F target genes: unraveling the biology.

  2004cited by this paper
• Cyclin E.

  2004cited by this paper
• Cyclin E ablation in the mouse.

  2003cited by this paper
• Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation.

  2003cited by this paper
• Cyclin E overexpression and amplification in human tumours

  2003cited by this paper
• Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase*

  2003cited by this paper
• Proliferation of cancer cells despite CDK2 inhibition.

  2003cited by this paper
• Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells

  2003cited by this paper
• Transcription: Sibling rivalry in the E2F family

  2002cited by this paper
• The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node

  2002cited by this paper
• Ki-67, Cyclin E, and p16 INK4 Are Complimentary Surrogate Biomarkers for Human Papilloma Virus-Related Cervical Neoplasia

  2001cited by this paper
• Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line

  2001cited by this paper
• Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 Ubiquitin Ligase

  2001cited by this paper
• Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.

  2000cited by this paper
• Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF.

  2000cited by this paper
• NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription.

  2000cited by this paper
• Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells.

  1999cited by this paper
• Cyclin E-CDK2 is a regulator of p27Kip1.

  1997cited by this paper
• Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

  1996cited by this paper
• Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes

  1995cited by this paper
• Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle

  1992cited by this paper
• Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.

  1992cited by this paper
• Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast.

  1991cited by this paper
• Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.

  1991cited by this paper
• Phase I Studies

  year unknowncited by this paper

• Aloperine exerts anti-ovarian cancer effects by regulating the tricarboxylic acid cycle and glycolysis: A comprehensive study integrating network pharmacology, molecular docking, metabolomics, and experimental validation.

  2026cites this paper
• Disulfidptosis-Associated CCNB2: A Prognostic Biomarker and Immune Microenvironment Modulator in Prostate Cancer

  2025cites this paper
• Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

  2025cites this paper
• BRPF1 inhibition reduces migration and invasion of metastatic ovarian cancer cells, representing a potential therapeutic target

  2025cites this paper
• Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception.

  2025cites this paper
• Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition

  2025cites this paper
• CCNE1 Promotes the Progression of Hepatic Precancerous Lesion and the Malignant Phenotype of Hepatocellular Carcinoma

  2025cites this paper
• Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

  2024cites this paper
• Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer

  2024cites this paper
• Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial.

  2024cites this paper
• An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes

  2024cites this paper
• Expanding the ligandable proteome by paralog hopping with covalent probes

  2024cites this paper
• Scutellaria baicalensis Georgi and Their Natural Flavonoid Compounds in the Treatment of Ovarian Cancer: A Review

  2023cites this paper
• Design, synthesis, and molecular docking of novel 1,3, 4-triaryl pyrazole derivatives bearing methylsulfonyl moiety with anticancer activity through dual targeting CDK2 and COX-2 enzymes

  2023cites this paper
• Evaluating the association of missense mutations in cyclin E1 and MYC genes with breast cancer using computational analysis

  2023cites this paper
• IMP-1 inhibits renal cell carcinoma 786-O cell growth by targeting EphrinB2 signaling pathway

  2023cites this paper
• Tasmanian devil cathelicidins exhibit anticancer activity against Devil Facial Tumour Disease (DFTD) cells

  2023cites this paper
• Circular RNAs in hepatocellular carcinoma: biogenesis, function, and pathology

  2023cites this paper
• Clinical CDK2 Inhibitors: Trends To Selectivity and Efficacy.

  2022cites this paper
• The potential of Lycium barbarum miR166a in kidney cancer treatment.

  2022cites this paper
• Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

  2022cites this paper
• Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer

  2022cites this paper
• Targeting DUSP activity as a treatment for high grade serous ovarian carcinoma.

  2022cites this paper
• RSF1 in cancer: interactions and functions

  2021cites this paper
• CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma

  2021cites this paper
• The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers

  2021cites this paper
• Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer

  2021cites this paper
• Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets

  2021cites this paper
• Clinical significance of CCNE1 copy number gain in acral melanoma patients

  2021cites this paper
• CCNE1 amplification among metastatic sites in patients with gynecologic high-grade serous carcinoma

  2020cites this paper
• Long Noncoding RNA RAET1K Enhances CCNE1 Expression and Cell Cycle Arrest of Lung Adenocarcinoma Cell by Sponging miRNA-135a-5p

  2020cites this paper
• Connexins: Key Players in the Control of Vascular Plasticity and Function.

  2020cites this paper
• MiR-23a-3p promoted G1/S cell cycle transition by targeting protocadherin17 in hepatocellular carcinoma

  2020cites this paper
• Reduced SKP1 Expression Induces Chromosome Instability through Aberrant Cyclin E1 Protein Turnover

  2020cites this paper
• Circular RNAs as miRNA sponges in triple-negative breast cancer: a systematic review

  2020cites this paper
• Circular RNA circ-CSPP1 regulates CCNE2 to facilitate hepatocellular carcinoma cell growth via sponging miR-577

  2020cites this paper
• TCF21: a critical transcription factor in health and cancer

  2020cites this paper
• miR-335-5p Regulates Cell Cycle and Metastasis in Lung Adenocarcinoma by Targeting CCNB2

  2020cites this paper
• Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53.

  2020cites this paper
• Cyclin E: a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle.

  2020cites this paper
• Mechanisms of Taxane Resistance

  2020influential citation
• HNRNPU Overexpression has Prognostic Value in Human Ovarian Cancer and Promotes Ovarian Cancer Cell Proliferation

  2020cites this paper
• OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1

  2020cites this paper
• Overexpression of CCNE1 confers a poorer prognosis in triple-negative breast cancer identified by bioinformatic analysis

  2020cites this paper
• Frequency of CDK2 , CCNE1 Copy Number Variation in Acral Melanoma and Implications for CDK Inhibitor in Targeted Therapy

  2020cites this paper
• OTT_A_245136 6255..6263

  2020cites this paper
• The regulation of dermal mesenchymal stem cells on keratinocytes apoptosis

  2020cites this paper
• A Comprehensive Review of Ovarian Serous Carcinoma

  2019cites this paper
• Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a molecular target in breast cancer: a therapeutic perspective of gynecological cancer

  2019cites this paper
• Genetic Characterization and Identification of Novel Treatment Targets in Anaplastic Thyroid Carcinoma

  2019cites this paper
• Mechanistic Insights Into DREAM and RB Control of the Cell Cycle

  2019cites this paper
• Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition

  2019cites this paper
• The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression

  2019cites this paper
• L‑carnitine alleviates oxidative stress‑related damage via MAPK signaling in human lens epithelial cells exposed to H2O2.

  2019cites this paper
• C-Phycocyanin elicited antitumor efficacy via cell-cycle arrest, apoptosis induction, and invasion inhibition in esophageal squamous cell carcinoma

  2019cites this paper
• Role of TMPRSS4 Modulation in Breast Cancer Cell Proliferation

  2019cites this paper
• Comprehensive Analysis of Mouse Cancer/Testis Antigen Functions in Cancer Cells and Roles of TEKT5 in Cancer Cells and Testicular Germ Cells

  2019cites this paper
• Optimising patient selection to improve outcome in advanced ovarian cancer

  2019cites this paper
• α-bisabolol enhances radiotherapy-induced apoptosis in endometrial cancer cells by reducing the effect of XIAP on inhibiting caspase-3

  2019cites this paper
• Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells

  2019cites this paper
• Novel Genomic Biomarker Candidates for Cervical Cancer As Identified by Differential Co-Expression Network Analysis

  2019cites this paper
• MiR-15b regulates cell differentiation and survival by targeting CCNE1 in APL cell lines.

  2019cites this paper
• Aryl‐urea fatty acids that activate the p38 MAP kinase and down‐regulate multiple cyclins decrease the viability of MDA‐MB‐231 breast cancer cells☆

  2019cites this paper
• Epithelial Tumors of the Ovary

  2019cites this paper
• Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling

  2019cites this paper
• Emerging serine-threonine kinase inhibitors for treating ovarian cancer

  2019cites this paper
• MicroRNA-107 inhibits proliferation of prostate cancer cells by targeting cyclin E1.

  2019cites this paper
• MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer.

  2019cites this paper
• Identification of key genes and pathways in uterine leiomyosarcoma through bioinformatics analysis.

  2018cites this paper
• Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells

  2018cites this paper
• Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

  2018cites this paper
• Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors

  2018cites this paper
• TNNT1 facilitates proliferation of breast cancer cells by promoting G1/S phase transition

  2018cites this paper
• A turning point in the fight against ovarian cancer?

  2018cites this paper
• Genetic profiles of different subsets of Merkel cell carcinoma show links between combined and pure MCPyV-negative tumors.

  2018cites this paper
• Clinical significance and biological roles of cyclins in gastric cancer

  2018cites this paper
• 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.

  2018cites this paper
• Mechanism of Cepharanthine Cytotoxicity in Human Ovarian Cancer Cells

  2018cites this paper
• Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy

  2018cites this paper
• MiR-138-5p targeting LIMK1 suppresses breast cancer cell proliferation and motility

  2017cites this paper
• Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data

  2017cites this paper
• CCNE1 EXPRESSION AND CA-125 LEVELS IN HIGH GRADE SEROUS CARCINOMA OVARY AT MOHAMMAD HOESIN GENERAL HOSPITAL PALEMBANG ; A SINGLE-INSTITUTION DESCRIPTIVE STUDY

  year unknowncites this paper